Nuti R, Vattimo A
Dtsch Med Wochenschr. 1981 Jan 30;106(5):149-52. doi: 10.1055/s-2008-1070275.
Synthetic human calcitonin was used in the treatment of 26 patients over a period of 1-14 months. 17 patients had Paget's disease of the bone, 6 postmenopausal osteoporosis and 3 Sudeck's syndrome. Subjective improvement (reduction of pain, improvement of mobility) was found in 15 patients with Paget's disease, in 4 females with postmenopausal osteoporosis and in all 3 patients with Sudeck's syndrome. Radiographic improvement of bone changes developed only very slowly. These results were confirmed by diminution of the exchangeable calcium pool indicating reduction of rates of osseous degradation. Calcitonin tolerance was acceptable. Transitory nausea and occasional vomiting occurred in 3 patients.
合成人降钙素用于26例患者的治疗,为期1至14个月。17例患有骨Paget病,6例患有绝经后骨质疏松症,3例患有苏戴克综合征。在15例骨Paget病患者、4例绝经后骨质疏松症女性患者以及所有3例苏戴克综合征患者中发现了主观改善(疼痛减轻、活动能力改善)。骨改变的影像学改善进展非常缓慢。可交换钙池的减少表明骨降解速率降低,证实了这些结果。降钙素耐受性尚可。3例患者出现短暂恶心和偶尔呕吐。